Q3 Total Revenue Grew 34% Year-over-Year to Approximately $41.7 million
Q3 Adjusted EBITDA Improved to approximately 3% of Revenue
Cash Position Remains Strong at over $19.0 Million
KITS Eyecare Reports Preliminary Third Quarter 2024 Results
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.